Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248104 | 0.77 | SRD5A1 (0.33) | — | |
| SCHEMBL3496791 | 0.76 | PPARA (0.53) | — | |
| SCHEMBL30968901 | 0.74 | CHRNA3 (0.42) | CHRNA3CHRNB2CHRNB4CHRNA7CHRNA4 | |
| SCHEMBL2304175 | 0.74 | CHRNA3 (0.42) | CHRNA3CHRNB2CHRNB4CHRNA7CHRNA4 | |
| SCHEMBL609618 | 0.72 | ABL1 (0.40) | CHRNA3CHRNB2CHRNB4CHRNA7CHRNA4 | |
| SCHEMBL18872333 | 0.72 | CACNA1I (0.37) | — | |
| SCHEMBL29411244 | 0.72 | SLC7A5 (0.48) | GRM4CHRNA3CHRNB2CHRNB4CHRNA7 | |
| SCHEMBL2302955 | 0.72 | SLC7A5 (0.48) | GRM4CHRNA3CHRNB2CHRNB4CHRNA7 | |
| SCHEMBL12225600 | 0.72 | CHRNA3 (0.41) | CHRNA3CHRNB2CHRNB4CHRNA7CHRNA4 | |
| SCHEMBL10676732 | 0.71 | GRM4 (0.39) | GRM4CHRNA3CHRNB2CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2709997-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889682-B2 | Inhibitors of bruton'S tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2013-02-21 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012156334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012156334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GRM4 4752/4885CHRNA3 4711/4885CYP11B1 2082/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | GRM4 2720/4885CHRNA3 4195/4885CYP11B1 2256/4885 |
| US-20130045965-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GRM4 4760/4885CHRNA3 4697/4885CYP11B1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.